<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00804830</url>
  </required_header>
  <id_info>
    <org_study_id>2007-001783-75</org_study_id>
    <nct_id>NCT00804830</nct_id>
  </id_info>
  <brief_title>Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer</brief_title>
  <official_title>Phase 2 Study With Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anaplastic Thyroid Cancer is a very aggressive disease. The investigators believe that
      angiogenesis is very important for these tumors to progress. Preclinical data is suggesting
      this. This is why we we prospectively want to treat these patients with avastin (and
      doxorubicin). However, local control is of major concern. Therefore, patients are initially
      treated with hyperfractionated radiotherapy and undergo surgery. Then they can enter this
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Anaplastic Thyroid Cancer have a poor prognosis. We will treat the patients
      initially with our standard radiochemotherapy, which consists of doxorubicin 20mg fixed
      dose/week and hyperfractionated radiotherapy 1,6 Gy twice daily up to 46 Gy in total. The
      first week during radiotherapy, they will also receive Avastin 15mg/kg. 1-2 weeks after
      radiotherapy patients will undergo surgery of their primary tumor. After this &quot;standard&quot;
      therapy patients can be included in this study. Treatment is 20 mg fixed dose doxorubicin q1w
      and avastin 15mg/kg q3w. Treatment will continue maximum 6 months or until progress or until
      intolerable side effects occur.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2-5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>2-5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Thyroid Neoplasms</condition>
  <condition>Carcinoma</condition>
  <condition>Thyroid Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w</description>
    <arm_group_label>chemotherapy</arm_group_label>
    <other_name>Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cytologically or histologically verified anaplastic thyroid cancer

          -  completed standard therapy

          -  operated with R0 or R1 surgery

          -  Performance Status 0-2 (if pulmonary mets PS 0-1)

          -  normal wound healing

          -  neutrophils &gt; 1,5 million/ml

          -  platelets &gt; 100 million/ml

          -  bilirubin &lt; 2 ULN

          -  creatinin &lt; 150mikromol/L

        Exclusion Criteria:

          -  PS 3-4 (if pulmonary mets 2-4)

          -  R2 resection of primary tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Tennvall, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep of Oncology, Lund University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jubileumskliniken, Sahlgrenska universitetsjukhuset</name>
      <address>
        <city>GÃ¶teborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dep of Oncology, Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2008</study_first_submitted>
  <study_first_submitted_qc>December 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2008</study_first_posted>
  <last_update_submitted>August 20, 2012</last_update_submitted>
  <last_update_submitted_qc>August 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adjuvant</keyword>
  <keyword>Anaplastic thyroid cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Thyroid Carcinoma, Anaplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

